ALPS Advisors’s Sarepta Therapeutics SRPT Stock Holding History

ALPS Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Buy	106,549 +21,080	+25%	+$399K	0.01%	537
2026 Q1	$1.86M	Sell	85,469 -568	-0.7%	-$11K	0.01%	420
2025 Q4	$1.85M	Buy	+86,037	New	+$1.81M	0.01%	406
2018 Q4	–	Sell	-1,554	Closed	-$251K	–	934
2018 Q3	$251K	Sell	1,554 -626	-29%	-$85.6K	﹤0.01%	906
2018 Q2	$288K	Sell	2,180 -84,505	-97%	-$7.97M	﹤0.01%	869
2018 Q1	$6.42M	Buy	86,685 +15,066	+21%	+$1M	0.05%	128
2017 Q4	$3.98M	Buy	+71,619	New	+$3.79M	0.03%	150

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ALPS Advisors's SRPT Position: Q2 2026 in Review

ALPS Advisors increased its Sarepta Therapeutics (SRPT) stake by 25% in Q2 2026, buying an estimated $399K and bringing the position to 106,549 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #537.

ALPS Advisors first reported a position in SRPT in Q4 2017 and has held it in 7 quarters since. The position peaked at $6.42M in Q1 2018. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

ALPS Advisors held 106,549 shares of Sarepta Therapeutics worth $1.91M as of Q2 2026.
ALPS Advisors bought 21,080 Sarepta Therapeutics shares in Q2 2026, an estimated $399K.
Sarepta Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #537 holding.
ALPS Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 7 quarters since.
ALPS Advisors's Sarepta Therapeutics position peaked at $6.42M in Q1 2018.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.